Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
biote Corp. logo

NASDAQ · BTMD

biote Corp.

Healthcare · Medical - Care Facilities

$1.12

Up+$0.11 (+9.82%)

Updated Nov 4, 2026, 11:02 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
136.76M
P/E ratio
3.11
Dividend yield
0.00%
52-week range
$1.00 – $2.98
Volume
90.49K
Avg. volume
121.8K

Price performance · BTMD

BTMD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

BTMD closed at $1.12 after 21 trading sessions, down 1.75% for the selected period.

Last close
$1.12
Period change
-1.75%
Period low
$1.03
Period high
$1.18
Daily close
View OHLC price history
BTMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.16$1.19$1.12$1.1290.49K
Nov 2, 2026$1.10$1.19$1.10$1.1398.07K
Oct 30, 2026$1.17$1.1981$1.105$1.1165.59K
Oct 29, 2026$1.14$1.20$1.1101$1.17127K
Oct 28, 2026$1.17$1.2445$1.15$1.1574.13K
Oct 27, 2026$1.15$1.20$1.1343$1.1856.75K
Oct 26, 2026$1.06$1.24$1.04$1.1594.1K
Oct 23, 2026$1.13$1.13$1.05$1.0794.95K
Oct 22, 2026$1.02$1.13$1.02$1.09109.75K
Oct 21, 2026$1.07$1.16$1.025$1.03131.97K
Oct 20, 2026$1.06$1.11$1.045$1.0742.56K
Oct 19, 2026$1.09$1.1231$1.04$1.0875.9K
Oct 16, 2026$1.10$1.14$1.08$1.08541.59K
Oct 15, 2026$1.14$1.15$1.10$1.1143.24K
Oct 14, 2026$1.06$1.2099$1.06$1.13144.79K
Oct 13, 2026$1.14$1.20$1.00$1.04387.35K
Oct 12, 2026$1.15$1.20$1.12$1.1463.33K
Oct 9, 2026$1.17$1.25$1.15$1.1545.58K
Oct 8, 2026$1.10$1.17$1.06$1.17149.7K
Oct 7, 2026$1.13$1.18$1.085$1.11194.96K
Oct 6, 2026$1.12$1.25$1.12$1.14231.34K

Latest BTMD news

The latest Smart Investors Daily articles mentioning BTMD.

Stock researchCompany · Overview

BTMD research

Overview

Company profile and research snapshot.

Company profile

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$8.62
Implied upside
—
Analysts
11
BTMD recent ratings
DateFirmRatingTarget
Aug 10, 2026B. Riley SecuritiesNeutral—
Aug 7, 2026TD CowenBuy—
Apr 16, 2026Truist SecuritiesBuy—
Mar 12, 2026TD CowenBuy—
Mar 12, 2026B. Riley SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call

IRVING, Texas, October 21, 2026--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide third quarter financial results on Wednesday, November 4, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By